%{{tag.tag}} {{articledata.title}} {{moment(articledata.cdate)}} @{{articledata.company.replace(" ","")}} comment A California-based %Biotech company turned heads on Wednesday after the company announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in %CysticFibrosis (CF) patients. According to the release, the company is on track to complete database lock, data analyses, and disclose top-line data in the first quarter of 2023. This sent shares of %AridisPharmaceuticals ($ARDS ) up to $0.9833/share (+9.26%) at the early session high. Keep you eyes on this one for sessions to come! Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.